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It has been recently reported that a large proportion of patients with familial amyotrophic lateral sclerosis (ALS) and frontotemporal
dementia (FTD) are associated with a hexanucleotide (GGGGCC) repeat expansion in the first intron of C9ORF72. We have assessed 1757
Italian sporadic ALS cases, 133 from Sardinia, 101 from Sicily, and 1523 from mainland Italy. Sixty (3.7%) of 1624 mainland Italians and
Sicilians and 9 (6.8%) of the 133 Sardinian sporadic ALS cases carried the pathogenic repeat expansion. None of the 619 regionally matched
control samples (1238 chromosomes) carried the expansion. Twenty-five cases (36.2%) had behavioral FTD in addition to ALS. FTD or
unspecified dementia was also detected in 19 pedigrees (27.5%) in first-degree relatives of ALS patients. Cases carrying the C9ORF72
exanucleotide expansion survived 1 year less than cases who did not carry this mutation. In conclusion, we found that C9ORF72
exanucleotide repeat expansions represents a sizeable proportion of apparent sporadic ALS in the Italian and Sardinian population,
epresenting by far the most common mutation in Italy and the second most common in Sardinia.
2012 Elsevier Inc. All rights reserved.
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c1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disorder of the adult life characterized by a progressive
loss of lower motor neurons at spinal and bulbar level and
of upper motor neurons. Its course is invariably fatal within
3 to 5 years from onset. While 5% to 10% of cases is
familial in nature (familial ALS), the majority of patients
present as apparently sporadic (sporadic ALS).
Recently, we found that a large hexanucleotide (GGGGCC)
repeat expansion in the first intron of C9ORF72, a gene located
on chromosome 9p21, is pathogenic in a large proportion of
patients with familial ALS and frontotemporal dementia
(FTD) of Finnish and European ancestry (Dejesus-Hernan-
dez et al., 2011; Renton et al., 2011). In these families, the
genetic defect is dominantly transmitted; however, muta-
tions of this gene have also been detected in a number of
patients with apparently sporadic ALS or FTD (Dejesus-Her-
andez et al., 2011; Renton et al., 2011). To date, little clinical
nformation is available about the characteristics of apparently
poradic ALS patients carrying C9ORF72 hexanucleotide re-
peat expansions.
The aim of the present report was to provide a detailed
genotype-phenotype description of sporadic ALS cases car-
rying the expansion including age at onset, gender, site of
onset, cognitive status, and survival.
2. Methods
A total of 1757 Italian sporadic ALS cases have been
collected thorough the Italian ALS Genetic Consortium
(ITALSGEN), which is a collaborative effort between 15
ALS centers throughout the Italian peninsula and the Med-
iterranean islands of Sicily and Sardinia. Of these, 133 were
of Sardinian ancestry, 101 were from Sicily, and the re-
maining 1523 were from mainland Italy. Of note, we pre-
viously reported the C9ORF72 repeat expansion status for
465 of these patients in our previous report (Majounie et al.,
in press). All cases included in the present study had anegative family history for ALS and were negative for
mutations in major ALS genes (SOD1, TARDBP, and FUS).
All cases had a diagnosis of definite, probable, probable
laboratory-supported, or possible ALS according to El Es-
corial revised criteria (Brooks et al., 2000).
Controls consisted of 402 neurologically healthy subjects
of mainland Italian ancestry, 61 of Sicilian ancestry, and
156 of Sardinian ancestry.
The clinical history of patients found to carry the
C9ORF72 expansion was systematically reviewed to iden-
tify details of the disease phenotype including gender, age
of onset, disease duration, disease variant, details of family
history, and the presence of cognitive impairment. Formal
cognitive evaluation was not systematically performed in
this series. In 66 nonexpanded cases the age at onset, the site
of onset, and the survival were not known.
2.1. C9ORF72 analysis
A repeat-primed polymerase chain reaction (PCR) assay
was used to screen the presence of the GGGGCC
hexanucleotide expansion in the first intron of C9ORF72 as
described in the original report (Renton et al., 2011). This
ssay rapidly and robustly determines whether a sample
arries the repeat expansion, but does not measure the actual
umber of repeats in the expansion. ALS-associated patho-
ogical expansions in C9ORF72 have been defined as
reater than 30 repeats.
.2. Statistical analysis
Continuous variables (i.e., age at symptom onset) were
ompared with t test and discrete variable (i.e., gender, site
of onset) with 2. Survival was calculated with Kaplan and
Meier curves and compared with log-rank test, using as end
point death or tracheostomy. For censored cases, the last
day of follow-up was November 1, 2011. Multivariable
analysis was performed with the Cox proportional hazards
model (stepwise backward). The following variables were
included in the model: age (included as continuous vari-
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3M. Sabatelli et al. / Neurobiology of Aging xx (2012) xxxable), gender (male vs. female), site of onset (bulbar vs.
spinal), ancestry (Italian vs. Sardinian), and C9ORF72 sta-
tus (expanded vs. not expanded). A p value  0.05 was
considered significant. All calculations were made with
SPSS version 18 (IBM Corporation, Chicago, IL, USA).
The study was approved by the ethical committees of the
participating centers. All patients signed a written informed
consent.
3. Results
3.1. Frequency of C9ORF72 pathological repeat
expansion in sporadic ALS
We tested 1523 mainland Italian patients, 101 Sicilian
patients, and 133 Sardinian patients diagnosed with spo-
radic ALS for the presence of the GGGGCC hexanucleotide
repeat expansion of the C9ORF72 gene using a repeat-
primed polymerase chain reaction assay. Fifty-five (3.6%)
of the mainland Italians carried the pathogenic repeat ex-
pansion, whereas 5 (4.9%) of the 101 patients with Sicilian
ancestry, and 9 (6.8%) of the 133 Sardinian sporadic ALS
cases were carriers. None of the 402 mainland Italian, 61
Sicilian, and 156 Sardinian control samples (1238 chromo-
somes) carried the expansion. The median number of re-
peats in mainland Italian and Sicilian controls was 3 (range,
0–23; interquartile range, 0–5), and in Sardinian controls
was 4 (range, 0–12; interquartile range, 0–5; see Supple-
mentary Fig. 1).
Evaluation of the pedigrees of sporadic ALS carrying the
pathological expansion did not reveal other cases of ALS.
However, FTD or unspecified dementia was detected in
first-degree relatives of ALS patients in 19 pedigrees
(27.5%). Moreover, we identified first degree relatives with
parkinsonism in 3 pedigrees, and with schizophrenia in 2
pedigrees.
3.2. Genotype-phenotype correlation
The clinical characteristics of the sporadic ALS cases
carrying C9ORF72 expansion are reported in Supplemen-
tary Table 1. Twenty-five cases (36.2%) had FTD in addi-
tion to their motor dysfunction. In all cases, FTD presented
with behavioral symptoms, while none of the cases had
features consistent with semantic dementia or progressive
nonfluent aphasia. Three cases had additional clinical symp-
toms of parkinsonism, with positive dopamine transporter
(DAT) scan, and 3 had psychotic symptoms (hallucinations
and delusions).
Gender distribution and site of onset were similar in
mutated and nonmutated cases (Table 1). Cases with
C9ORF72 expansion had a slightly lower median age at
onset than those without the expansion (59.0 [interquartile
range, 50.0–65.6]; range, 32.9–83.0, vs. 62.8 [interquartile
range, 54.0–69.7]; range, 20.5–89.6) (p  0.002) (Fig. 1). Tab Co Ge Sit
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Survival of cases carrying the C9ORF72 hexanucleotide
expansion was 1 year shorter than that of cases who did not
carry this mutation (C9ORF72 expanded cases, median sur-
ival time, 2.7 years; 95% confidence interval [CI], 2.1–3.3;
ot expanded cases, median survival time, 3.6; 95% CI,
.3–3.8; p  0.03) (Fig. 2). The negative effect of
9ORF72 expansion on survival persisted in the Cox mul-
ivariate model (C9ORF72 status, not expanded vs. ex-
anded hazard ratio, 1.79; 95% CI, 1.26–2.98; p  0.008).
. Discussion
C9ORF72 hexanucleotide repeat expansions have been
etected in 3.7% of mainland Italian sporadic ALS of this
eries, which is representative of the Italian population, as it
ncludes ALS cases originating from all Italian regions.
herefore, C9ORF72 hexanucleotide repeat expansions is
y far the most common mutation in apparently sporadic
LS in the Italian population (Chiò et al., 2008; Corrado et
l., 2010; Del Bo et al., 2009; Lai et al., 2011).
The frequency of Italian sporadic ALS carrying
9ORF72 hexanucleotide repeat expansion is lower than
hat reported in Finland (Renton et al., 2011), and in other
orth-European populations, such as Britons, Irish, and Ger-
ans, as well in Caucasian Americans (Dejesus-Hernandez
t al., 2011; Gijselinck et al., 2012; Majounie et al., in press;
enton et al., 2011).
Fig. 1. Cumulative probability of disease onset according to the age of
patients. Comparison between sporadic amyotrophic lateral sclerosis
(ALS) patients with hexanucleotide repeat expansion of the C9ORF72
gene or unknown genetic mutation (p  0.003).In sporadic ALS of Sardinian ancestry, C9ORF72 repeatxpansions were more frequent than in mainland Italy, ac-
ounting for about 7% of cases, but they are less frequent
han the A382T missense mutations of the TARDBP gene,
hich accounted for about 23% of sporadic ALS in the
ame population (Chiò et al., 2011; Orrù et al., 2012). The
high frequency of the C9ORF72 mutation in Sardinia is
likely to be related to the “magnification” of pathological
genes in isolated populations, due to the so-called genetic
drift phenomenon combined to the founder effect.
Sporadic ALS cases carrying the C9ORF72 hexanucle-
tide repeat expansion were phenotypically different from
hose not carrying the expansion. First, they were signifi-
antly younger, confirming previous observation in familial
LS patients carrying the same expansion (Chiò et al.,
012; Majounie et al., in press). Second, they had a more
ggressive clinical course, with a median survival approxi-
ately 1 year less than cases without the expansion. Ac-
ording to the Cox multivariable analysis, the negative
ffect of C9ORF72 mutations on ALS survival is indepen-
ent of age and site of onset. However, we did not include
n the analysis the presence of FTD, a known negative
rognostic factor in ALS (Elamin et al., 2011), which is
nown to have a higher frequency in ALS cases with
9ORF72 hexanucleotide repeat expansion than in those
ithout this expansion (Dejesus-Hernandez et al., 2011;
enton et al., 2011). Finally, a third of cases with the
xpansion manifested cognitive impairment, consistent with
revious reports of a high rate of FTD in this patient group.
The identification of the C9ORF72 expansion in appar-
Fig. 2. Cumulative survival probability from time of disease onset. Com-
parison between sporadic amyotrophic lateral sclerosis (ALS) patients with
hexanucleotide repeat expansion of the C9ORF72 gene and patients with-
out known genetic mutation (p  0.023). Blue, unknown mutation; green,
C9ORF72. Marks are censored patients.
5M. Sabatelli et al. / Neurobiology of Aging xx (2012) xxxently sporadic ALS may have different explanations, in-
cluding poor diagnosis in the past, lack of knowledge of
family history, mutation carriers in previous generations
dying of other diseases prior to developing motor neuron
degeneration, reduced penetrance of the gene, and even
varying phenotypic manifestations among mutation carriers
within the same family (Traynor and Singleton, 2009). An
incomplete penetrance of C9ORF72 has been reported in a
large multinational study (Majounie et al., in press). How-
ever, the likely familial nature of these apparently sporadic
cases is supported by several findings. First, the gender
distribution of the cases carrying the C9ORF72 repeat ex-
pansion in our sporadic series is not different from that
expected for an autosomal dominant mutation. Second, the
frequent identification of relatives with FTD or dementia in
the patients’ pedigrees support the notion that the C9ORF72
hexanucleotide expansion may manifest with different mo-
tor or cognitive phenotypes in the same pedigree. This
observation implies that the definition of familial ALS
should be enlarged to include patients with a positive family
history for FTD, modifying the proposed criteria for defi-
nition of familial ALS (Byrne et al., 2011). Third, previous
data indicate that ALS and FTD patients carrying the
C9ORF72 mutation share a common haplotype and that all
cases are in fact derived from a single founder (Mok et al.,
2012).
In conclusion, we found that C9ORF72 hexanucleotide
repeat expansions represent a sizeable proportion of appar-
ent sporadic ALS in the Italian and Sardinian population,
representing by far the most common mutation in Italy and
the second most common in Sardinia, after the A382T
missense mutation of the TARDBP gene. The high fre-
quency of familial aggregates of ALS and dementia in the
pedigrees of these apparently sporadic cases with the
C9ORF72 mutation support the notion that most of these
cases are in fact familial. An accurate study of the family
history of ALS patients, as well the identification of comor-
bid FTD, may therefore be useful to clinically identify the
possible carriers of this mutation.
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